TrialJournal of diabetes investigation2018

Dipeptidyl peptidase-4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: Results from a multicenter, 12-week, open label, randomized controlled study in Japan (PREFERENCE 4 study).

Hitoshi Ishii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.